Michael J Elliott, MBBS, PhD, FRACP Vice President and Entrepreneur in Residence Janssen Pharmaceuticals, a division of Johnson & Johnson May 2012
Dr Elliott is a physician-scientist and drug developer. He has spent much of his career in the biotech and pharmaceutical industry, working in large and small companies. His J&J career includes 7 years at Centocor, where he led the clinical development of Centocor's monoclonal antibody (mAb) products in immune and inflammatory disorders. Foremost amongst these were the development and regulatory approval of the anti-TNF mAb infliximab (REMICADE) in rheumatoid arthritis, Crohn's disease, ulcerative colitis and other inflammatory indications, and of the follow-on anti-TNF mAb, golimumab (Simponi) in a range of rheumatic diseases. His group also led clinical development of the first in class anti-IL-12/23 mAb, ustekinumab (Stelara) for the treatment of psoriasis. More recently,
Dr Elliott served as General Manager and Site Head at TransForm Pharmaceuticals, a J&J company focused on high throughput drug formulation, and served as a member of the J&J Corporate Office of Science and Technology. In January 2012, Dr Elliott transitioned to the role of Janssen Entrepreneur in Residence at Polaris Ventures, where he is working to build a portfolio of early stage pharma and biotech companies of interest to both Janssen and Polaris.
Dr Elliott earned his medical degree (MBBS) and PhD from the University of Adelaide, Australia, and is a Fellow of the Royal Australasian College of Physicians. His early scientific work at the University of Adelaide and at the Walter and Eliza Hall Institute in Melbourne included studies